Oncolytics Biotech announced positive top-line data for the endpoints in its double blinded, randomized clinical study examining Reolysin in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers. The analysis showed a median progression free survival of 94 days in the test arm, versus 50 days in the control arm. The test arm maintained a PFS benefit over the control arm through five cycles of therapy. The side effects experienced by patients in the test arm of the study were consistent with expectations based on outcomes of earlier clinical studies using Reolysin. The drug was considered safe and well-tolerated by patients.